Whether use of various types of hormonal contraception (HC) affect risk of HIV acquisition is a critical question for women's health. For this systematic review, we identified 22 studies published by January 15, 2014 which met inclusion criteria; we classified thirteen studies as having severe methodological limitations, and nine studies as "informative but with important limitations". Overall, data do not support an association between use of oral contraceptives and increased risk of HIV acquisition. Uncertainty persists regarding whether an association exists between depot-medroxyprogesterone acetate (DMPA) use and risk of HIV acquisition. Most studies suggested no significantly increased HIV risk with norethisterone enanthate (NET-EN) use, but when assessed in the same study, point estimates for NET-EN tended to be larger than for DMPA, though 95% confidence intervals overlapped substantially. No data have suggested significantly increased risk of HIV acquisition with use of implants, though data were limited. No data are available on the relationship between use of contraceptive patches, rings, or hormonal intrauterine devices and risk of HIV acquisition. Women choosing progestin-only injectable contraceptives such as DMPA or NET-EN should be informed of the current uncertainty regarding whether use of these methods increases risk of HIV acquisition, and like all women at risk of HIV, should be empowered to access and use condoms and other HIV preventative measures. Programs, practitioners, and women urgently need guidance on how to maximize health with respect to avoiding both unintended pregnancy and HIV given inconclusive or limited data for certain HC methods. Published by Elsevier Inc.
Introduction
Whether various types of hormonal contraception (HC) affect the risk of HIV acquisition remains a critical question for women's health, particularly in populations where HIV is common. In 2012, the World Health Organization (WHO) convened a group of 75 experts to review epidemiological, biological, and other data on this issue, and concluded by consensus that WHO should recommend no restriction on use of any method of HC for women at high risk of HIV. However, the group added a clarification that, because of the inconclusive nature of the evidence relating to progestin-only injectables, women at high risk for HIV who choose progestin-only injectables should be strongly advised to always use male or female condoms and to take other HIV preventive measures (see technical statement [1] for full clarification).
The systematic review of epidemiological data relating to HC and HIV acquisition conducted for the 2012 WHO meeting included all relevant studies published (or in press) by December 15, 2011 [2] . Separate systematic reviews examined the epidemiological evidence on two related issues: whether various methods of HC affect HIV disease progression in women living with HIV [3] or female-to-male HIV transmission [4] .
Following the 2012 WHO consultation, the global health community responded with new modeling analyses [5] [6] [7] [8] , anatomical, microbiological, and immunological data [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , supplementary epidemiological analyses [25, 26] , commentaries [27] [28] [29] , overviews and guideline updates based on the systematic reviews [30] [31] [32] [33] , technical briefings [34] , and analytical recommendations for future observational analyses of HC and HIV acquisition [35] . Conversations continue about the feasibility and scientific benefit of a randomized trial of various HC methods and HIV risk [28, 36, 37] .
This issue is of substantial public health importance: for example, one impact simulation model estimated that if injectable contraception increases HIV risk by 20%, this would contribute to 27,000 additional infections per year, and that a doubling of HIV risk due to injectables would lead to an additional 130,000 HIV infections per year -the vast majority of which would occur in southern and Eastern Africa [5] . On the other hand, the same model estimated that if there is no causal effect of injectable contraception on HIV acquisition, but injectable use decreases due to fears of this possibility (and is not replaced by more effective contraceptive alternatives), we could expect a large increase in unintended pregnancies, unsafe abortions, unintended births, and at least 16,000 more maternal deaths per year worldwide, largely in southern and eastern Africa and southern Asia.
Therefore, it is imperative that new data on this issue is continually assessed and incorporated into our overall understanding of this complex body of literature, to ensure that contraceptive users, health care providers, and policy makers have the maximum amount of information available when making decisions. This paper updates the previous systematic review on HC and HIV acquisition in women by incorporating new epidemiological evidence published between December 15, 2011 , and January 15, 2014. Our goal was addressing the question of whether specific methods of HC influence a woman's risk of HIV acquisition. Data included in this systematic review were presented at a WHO meeting in March 2014. Official WHO guidance on hormonal contraception and HIV stemming from that meeting is expected to be disseminated in mid-2014. This systematic review was conducted independently of the WHO guidance development process, and served as an input in those deliberations.
Methods
We conducted this systematic review according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [38] .
Inclusion criteria
We included published primary research reports on women who were HIV-negative at baseline in longitudinal studies (observational studies or randomized trials) which measured incident, laboratory-confirmed HIV infection among women who used a specific method of HC [injectables, oral contraceptives (OCs), implants, patches, rings, or levonorgestrel intrauterine devices (IUDs)] compared with incident HIV infection in women who used either a non-hormonal contraceptive method (e.g., condoms, sterilization, withdrawal, etc.) or did not use a contraceptive method.
We determined a priori that any study comparing incident HIV infections among HIV-negative women using one specific method of HC against HIV-negative women using another method of HC (i.e., in a head-to-head comparison), would provide indirect evidence of risk, and would thus be discussed separately. We excluded cross-sectional studies and studies that assessed only emergency contraception (which is not typically used on a continual basis). We did not include conference abstracts or other reports not published in the peer-reviewed literature.
Search strategy and data extraction
We relied upon our earlier systematic review to identify articles published prior to December 15, 2011 , and searched PubMed and Embase for relevant articles published in any language between December 15, 2011 and January 15, 2014. We also hand-searched reference lists of related studies. Appendix A details the complete search strategy. CBP conducted the literature search and identified potentially relevant articles; CBP and SJP read full text articles to determine eligibility for inclusion. We used standardized abstraction forms developed and used in a previous review to extract relevant data [2] . When we needed to clarify details of a particular analysis, we attempted to contact the study authors directly.
Quality assessment
For comprehensiveness, we reviewed all studies that met our inclusion criteria. However, many studies had severe methodological flaws, and were considered unlikely to contribute meaningfully to the evidence base. Therefore, our main analysis focused on the studies we considered most methodologically robust, using the study quality assessment framework defined below. However, we note that all studies had important limitations and should be considered in that context. All authors participated in updating the study quality assessment framework and in classifying each study as either "informative but with important limitations" or "unlikely to inform the primary question."
Studies were considered "unlikely to inform the primary question" if they had one or more of the following flaws: number of users of another HC method (except in an intentional head-to-head comparison of a specific HC method versus another specific HC method). o The interval of time between study visits ("intersurvey interval") was longer than 6 months, with contraceptive use measured only at each interval endpoint (and thus providing only limited information about possible contraceptive switching during the intersurvey interval). (Note: if variation in length of intersurvey interval occurred within an individual study, such that some intervals were 6 months or less and other intervals were longer than 6 months, we included only data from intervals that were 6 months or less).
Studies considered "informative but with important limitations" had none of the flaws described above.
Graphical summaries
We created forest plots using Microsoft Excel 2007 (Microsoft, Redmond, WA, USA) to display the estimates from each study of the association between various HC methods and HIV risk, and generated funnel plots using Review Manager 5 [39] . We created graphics to display all available studies of a given method (i.e., OCs, injectables, or implants), as well as separate graphics to display only studies considered "Informative but with important limitations". We declined to include a statistical meta-analysis of these observational data for methodological reasons. For example, experts note that in observational data "potential biases in the original studies, relative to biases in randomized controlled trials, make the calculation of a single summary estimate of effect of exposure potentially misleading." [40] However, such efforts are the focus of ongoing work by other groups [28] .
Where possible, we have presented estimates for disaggregated HC methods, and included both Cox and marginal structural model (MSM) estimates when both were provided. We emailed authors of "informative but with important limitations" studies which included women from South Africa (where use of both types of injectable, DMPA and NET-EN, is common) but which did not report separate estimates for each, and requested disaggregated estimates where possible. Disaggregated estimates of effect have reduced statistical power but adj, adjusted; CSW, commercial sex worker; HR, hazard ratio; HSV2+, seropositive for herpes simplex virus 2; IRR, incidence rate ratio; OR, odds ratio; RCT, randomized control trial.
⁎
Studies considered "informative but with important limitations" included adjustment for condom use (at minimum), and clear measurement of exposure to hormonal contraception (as defined in the methods section).
are of more clinical importance, an important consideration given the potential for different biological effects by contraceptive type or formulation. All estimates from each study are reported in Tables A1 and A2. 3. Results
All included studies
Twenty eligible reports were included in the previous review [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] , and out of 400 references retrieved in our updated search (Fig. 1) , we identified one new eligible subanalysis of a previously included study [61] and two new eligible studies [62, 63] . None of these three new analyses were derived from studies designed specifically to assess the relationship between HC and HIV acquisition; all were secondary data analyses, and each included data from African women. None of the studies included head-to-head comparisons of different HC methods.
Among 22 included studies (represented by 23 reports), 18 included estimates specific to OCs [41-,47-53,57-60,62,63] , 16 included estimates specific to injectable contraception [41, 42, [48] [49] [50] [51] [52] [53] [54] [55] [57] [58] [59] [60] 62, 63] , and two did not distinguish between methods of HC although the investigators noted that most of the HC users used injectables [46, 56] . No eligible studies assessed the contraceptive patch, ring, combined injectable, or levonorgestrel IUD. Table A1 briefly describes all 23 reports (of 22 eligible studies) and notes whether they met criteria for being "informative but with important limitations". Fig. 2 displays the estimates from eighteen studies for OCs and Fig. 3 shows the estimates for injectables (two studies with non-specified methods of HC are included with the sixteen that reported estimates specific to injectables). In Figs. 2 and 3 all studies are displayed, regardless of methodological quality, and are shown in decreasing order of effect size.
Studies considered "informative but with important limitations"
Of 22 included studies, we considered thirteen "unlikely to inform the primary question" [43] [44] [45] [46] [47] [48] [49] [50] [51] 55, 56, 58, 63] , and nine "informative but with important limitations" (Table A2 ) [41, 42, [52] [53] [54] 57, [59] [60] [61] [62] 64] . Each of the "informative but with important limitations" studies included or assessed the need for statistical control for some measure of condom use, age, number of sexual partners, and genital symptoms or genital infection. Other factors, such as marital status, frequency of sexual encounters, or partner risk, were accounted for only in some of the studies (Table A3) .
Oral contraceptives
Of the eight "informative but with important limitations" studies that assessed OCs (Fig. 4) , one reported a significant increase in risk [p=.05; adjusted hazard ratio (adjHR) 1.5, 95% CI 1.0-2.1] [52] . The other studies reported nonsignificant estimates [ranging from adjusted incidence rate ratio (adjIRR) 0.66, 95% CI 0.09-4.78 to adjHR 1.80, 95% CI 0. 47-5.66 ] [41, 42, 53, 57, 59, 60, 62, 64] . No substantial differences were observed between combined oral contraceptives (COCs) and progestin-only pills (POPs) in the one study that disaggregated these methods [62] .
Injectables
Of the nine "informative but with important limitations" studies for injectables, four reported a significant increase in risk with injectables [42, 52, 57, 59] , though the statistical significance of one of these studies depended upon the statistical method used. In that study, the association was significant when MSM was used [57] , but non-significant when a Cox proportional hazards model was used [64] . The confounders adjusted for in each of these two statistical models differed slightly (Fig. 5) [57, 64] . Estimates from studies considered informative but with important limitations that reported significant findings for injectables ranged from adjHR 1.48, 95% CI 1.02-2.15 (specific to DMPA) [57] to adjHR 2.54, 95% CI 1.61-3.97 (specific to NET-EN) [42] . Five studies reported non-statistically significant estimates of effect in their primary analyses [41, 53, 54, 60, 62] [65] similar to the primary findings but with wider confidence intervals; this sub-analysis was based on four seroconverters assumed to be using DMPA (estimate from this restricted sub-analysis not shown in figures to avoid loss of data due to fewer endpoints; complete disaggregation into DMPA and NET-EN users was not possible in this analysis).
Of seven studies reporting DMPA-specific estimates, two reported significantly increased risks (ranging from to adjHR 1.61, 95% CI 1.10-2.37 [42] to adjHR 1.73, 95% CI 1.28-2.34 [52] ; one reported a significantly increased risk under an MSM statistical approach (adjHR 1.48, 95% CI 1.02-2.15) but a non-significant increased risk under a Cox proportional hazards model (adjHR 1.25, 95% CI: 0.89-1.78) [57, 64] ; two reported non-significant elevated estimates (adjHR 1.27, 95% CI 0.93-1.73 and adjHR 1.28, 95% CI 0.90-1.82) [60, 62] ; and two reported non-significant decreased estimates (adjIRR 0.46, 95% CI 0.06-3.79 and adjHR 0.75, 95% CI 0.33-1.68) (Fig. 6) [53, 54] . Same as above.
(continued on next page) 375 (continued on next page) 377 adj, adjusted; HR, hazard ratio; IRR, incidence rate ratio; LTFU, loss to follow-up; OR, odds ratio.
Original references retrieved (published between December 15, 2011 and January 15, 2014) n = 400
Reports excluded based on title/abstract review n = 397
Reports assessed for eligibility n = 3
Reports excluded n = 0
New reports included (n = 3) 2 new studies 1 sub-analysis of a previously included study Fig. 1 . Study selection. Note: We relied upon the search from a previous systematic review [2] to identify all relevant studies published prior to December 15, 2011. Fig. 2 . Use of oral contraceptives and HIV acquisition (all 18* studies, regardless of quality). Error bars show 95% CIs. Studies are arranged in order of decreasing magnitude of risk estimate, except if a single study disaggregated POPs and combined oral contraceptives [COCs] , in which case both estimates are adjacent (as indicated by a box around the study identifiers). For studies which reported both Cox and MSM estimates, both estimates are displayed on a single line (also identified by bracket signs). OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio. * Data from Saracco and colleagues' study are not shown because risk could not be calculated since no seroconversions occurred in the hormonal contraception group. † Analysis showed statistically significant findings at p=.05 (marker also displayed in red). ¥ Different statistical models adjusted for slightly different confounders.
Of five studies reporting NET-EN estimates, one reported a significantly increased risk (adjHR 2.54, 95% CI 1.61-3.97) [42] ; three reported non-significant elevated estimates (ranging from adjHR 1.33, 95% CI 0.76-2.33 to adjHR 1.76, 95% CI 0.64-4.84) [53, 54, 62] ; and one reported nonsignificant decreased estimates (adjHR 0.87, 95% CI 0.60-1.25 or adjHR 0.92, 95% CI 0.64-1.32, depending upon the statistical model used) (Fig. 7) [60] .
Of five studies that provided separate estimates for both DMPA and NET-EN (Fig. 5) , four reported estimates within the same study for NET-EN that were slightly or substantially higher than the DMPA estimates [42, 53, 54, 62] , while one study reported an estimate for NET-EN that was lower than for DMPA [60] .
Implants
Data on implants were limited. Only one study was classified as "informative but with important limitations", and it reported a non-significantly increased risk of HIV acquisition with implants, with a wide 95% confidence interval (adjHR 1.6, 95% CI 0.5-5.7) [66] .
Effect modification
One study by Morrison et al. reported that both DMPA and OCs were associated with increased HIV acquisition in women aged 18-24, but not in women aged 25 and older [57] . However, most studies have not detected evidence for effect modification by age [52] [53] [54] 59 ], including the secondlargest analysis to date (p=.60) [62] .
Similarly, the Morrison et al. study reported that DMPA was associated with increased HIV risk (adjHR 4.5, 95% CI 2.0-10.2) in HSV2-negative, but not HSV2-positive women (adjHR 1.0, 95% CI 0.7-1.6) [57] . Other studies have not found evidence for effect modification by HSV2 status [52, 59] , including a study of 2057 HSV2-negative women and 2856 HSV2-positive women (interaction term p=.21 for the effect of DMPA on HIV acquisition) [62] .
The Morrison et al. study also reported a significant interaction by study site (point estimates for both OCs and DMPA were above 1.0 in Uganda, but below 1.0 in Zimbabwe) [64] (an interaction that was not assessed in a later MSM analysis [57] ). That study reported no effect modification by reported condom use at baseline, by participant behavioral risk, or by prevalent chlamydia or gonorrhea [64] . Fig. 3 . Use of injectable contraceptives and HIV acquisition (all 18 studies, regardless of quality). Error bars show 95% CIs. Studies are arranged in order of decreasing magnitude of risk estimate, except if a single study provided disaggregated estimates for DMPA and NET-EN, in which case both estimates are adjacent (as indicated by a box around the study identifiers). For studies in which both Cox proportional hazards (Cox) and marginal structural model (MSM) analyses were reported, both are displayed on a single line (also identified by bracket signs containing two estimates), except for one study in which both Cox and MSM estimates for both DMPA and NET-EN separately were unavailable [62, 82] . OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio. *Analysis showed significant findings at p=.05 (marker also displayed in red). † Estimate for Cox model taken from slightly updated analysis which controlled for total number of unprotected sex acts. § Unpublished estimates disaggregated by injectable type. ¥ Different statistical models adjusted for slightly different confounders. BV, bacterial vaginosis; SW, sex worker; GUD, genital ulcer disease; HPV, human papillomavirus; HSV2, seropositive for herpes simplex virus 2; "all HIV+" -all partners were HIV positive as data were collected in study of serodiscordant couples. ⁎ Some confounders were considered but not controlled for due to a lack of confounding in those data; and some factors listed on this table are not relevant to all studies (i.e., site or race in homogeneous populations). † While most confounding factors are detailed in the original analysis [59] , the sensitivity analysis reported in a subsequent publication [61] added a control for total number of unprotected sex acts. , in which case both estimates are adjacent (as indicated by a box around the study identifiers). For studies which reported both Cox proportional hazards (Cox) and marginal structural model (MSM) estimates, both estimates are displayed on a single line (also identified by bracket signs). OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio. *Analysis showed significant findings at p=.05 (marker also displayed in red). ¥ Different statistical models adjusted for slightly different confounders.
Discussion

Methodological considerations in studies considered informative but with important limitations
Discussion of multiple key methodological considerations, such as potential for confounding, frequency and accuracy of variable measurement, aim of data collection, and statistical power and precision is available in our previous review [2] . Below, we expand upon the discussion on the handling of confounding by condom use, and provide an overview of considerations related to "total" and "direct" effects.
Considerations on measurement and parameterization of condom use
Analytic approaches to addressing potential confounding by condom use vary considerably across studies (Tables A1  and A2) , and is one of several reasons why study findings may vary. Reliable, valid, self-reported measurement of condom use is difficult: individuals may not remember whether, how often, and with whom they used condoms over a given time period; they may deliberately misreport due to embarrassment or social desirability bias [67] ; or they may unintentionally misreport (e.g., if they experience an unrecognized condom failure). Adjustment for a poorlymeasured confounding variable can in theory lead to adjusted estimates of effect which are more biased than the unadjusted estimates [68] .
Studies approached the issue of condom use in different ways. For example, one study restricted analysis to time periods in which no condom use was reported for either contraception or HIV prevention, in an attempt to minimize the potential for differential condom use between users and non-users of HC [63] . Some studies attempt to control statistically for some measure of condom use, such as the proportion of unprotected sex acts, or "never-sometimesalways" condom use. Studies varied with respect to whether questions about condom use were pertinent to the entire intersurvey interval, or only a subset of time during that interval. Some studies asked only about condom use during the most recent sex act and assumed this to be representative of participants' "typical" condom use. This last measure may reduce recall bias, but cannot eliminate intentional or unintentional misreporting; a recent review noted that in several studies semen was detected on vaginal swabs taken from 6-36% of women who reported no sex in the past 2 days, and in 13-39% of women who reported protected sex only [69] . Studies are arranged in order of decreasing magnitude of risk estimate, except if a single study disaggregated DMPA and NET-EN, in which case both estimates are adjacent (as indicated by a box around the study identifiers). For studies in which both Cox proportional hazards (Cox) and marginal structural model (MSM) analyses were reported, both are displayed on a single line (also identified by bracket signs), except for one study in which both Cox and MSM estimates for both DMPA and NET-EN separately were unavailable [62, 82] . OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio. *Analysis showed significant findings at p=.05 (marker also displayed in red). † Estimate for Cox model taken from slightly updated analysis which controlled for total number of unprotected sex acts. 
Direct versus total effects
As discussed in previous work [35] , the analytic approach used by an epidemiologic study has implications for the interpretation of its findings. In particular, model results from reports reviewed here may be estimating a "direct effect" of HC on HIV not mediated by sexual behaviors (which can be roughly conceived of as an estimate of the HIV acquisition risk per coital act unprotected by condoms, comparing HC users to non-users), the "total effect" (which would include these biological effects as well as behavioral changes that may be affected by HC use, such as decreased condom use or increased coital frequency), or neither (due to vague or poor model specification). The authors of this review determined that the "direct effect" (representing a more biological effect) is more desirable for the purpose of the World Health Organization Medical Eligibility Criteria for Contraceptive Use, which is intended to provide global guidance for policy makers. Unfortunately, estimating direct effects may require statistical assumptions additional to those necessary to estimate total effects.
While some argue that a "total effect" is useful to understand the full impact of a given HC method on HIV acquisition, behavioral changes stemming from use of HC may be specific to geography, culture, socioeconomic status, and other factors. Studies estimating a total effect may be less generalizable (if behaviors are affected differently in different populations), and may also be less informative for women for whom use of HC might modify their behavior in ways not represented by population averages. For example, a woman whose partner has always refused to use condoms will not reduce condom use as a result of HC initiation, even if most women who initiate HC reduce condom use. DMPA may be an important option for such a client if no direct effect of DMPA on HIV acquisition is expected, even if a total effect (mediated by reduced condom use) is expected. Thus, direct effects (which are not mediated by behaviors of individuals) may be of more use for individual decisionmaking, and are thus preferred in this discussion.
No published study has explicitly stated whether the analysis attempts to estimate total or direct effects. We assumed that MSMs are generally estimating total effects [70] and time-updated Cox models, which adjust for timevarying mediators such as condom use, are estimating something closer to direct effects. Nonetheless, we included MSM estimates in this review in the hopes of contextualizing direct effects. Although the models should theoretically produce different results, in practice most MSM estimates were very similar to adjusted Cox effects from the same studies. This suggests that mediation by measured sexual behavior was not substantial in this setting: however, since sexual behavior may have been mismeasured, it would be rash to conclude that there is no mediation per se. 
Modifications to quality framework used in previous review
As noted elsewhere, it is imperative to continually refine quality assessment criteria as this complex body of literature continues to grow [35] . For example, older systematic reviews of this issue may have included cross-sectional studies; doing so currently would add little to what is known. As such, we modified the study quality assessment framework used in the previous systematic review [2] . Specific modifications included: (1) relaxing our stipulations about adequate control for condom use (rationale provided below); (2) considering studies lower quality if one out of two (instead of two out of three) major flaws existed; (3) no longer specifying the level of loss to follow up that would be considered a major flaw (as the cutoff chosen could be viewed as arbitrary), and (4) providing additional specificity to our definition of "unclear measurement of exposure to HC," by newly including a requirement that the intersurvey interval be less than or equal to 6 months (or, if over 6 months, that detailed information on use of contraceptives in the interim period be collected and analyzed).
While a Cochrane review estimated that consistent condom use decreased heterosexual HIV transmission by 80% as compared with no condom use [71] , a study examining four different measures of condom use (condom use since last visit, condom use at last sex, frequency of condom use, and count of unprotected acts) found that no measure of condom use was significantly associated with reduced risk of sexually transmitted infections or HIV. All four measures were significantly correlated with reduced pregnancy risk; the strongest protective association was observed with the frequency of use condom variable [72] . Since no measurement of condom use has been validated as superior, we did not distinguish between methods of handling condom use, so long as some attempt was made to address this issue.
Limitations
All currently available epidemiological data on this issue come from observational studies and are vulnerable to residual confounding, which can mask a real effect or generate a spurious effect. Most currently available information relates to OCs and injectables (including DMPA and NET-EN). Separation of data according to specific hormonal content or formulation is not consistently performed across studies. Future analyses should provide disaggregated estimates, given that different hormonal formulations may have different biological effects on risk of HIV acquisition [35] . Data are extremely limited for implants, and no data are available for contraceptive patches, rings, or hormonal IUDs. analyses were reported, both are displayed on a single line (also identified by bracket signs). IRR, incidence risk ratio. HR, hazard ratio. *Analysis showed significant findings at p=.05 (marker also displayed in red). § Unpublished estimates disaggregated by injectable type; only disaggregated Cox estimates provided, disaggregated MSM estimates not possible due to violation of the positivity assumption.
Numerous measurement challenges remain in this body of literature, including of measurement of exposure and of potential confounders. For example, measurement of exposure to OC use (which requires daily action by the user) is more challenging than measurement of exposure to injectable contraceptive use (which requires user action only every 3 months). In some HIV prevention trials, women reporting OC use demonstrate comparable pregnancy incidence to women using no contraceptive method; raising the possibility of limited or inconsistent actual exposure to OC use [73] . Thus, the possibility exists that the null effect of OCs reported in most studies reflects a lack of actual exposure, rather than a true lack of association between OCs and risk of HIV acquisition. On the other hand, while pregnancy risk by contraceptive type is not consistently reported, some studies in this review demonstrate a reduction in pregnancy risk among OC users [41] . Given this issue, it is recommended that future observational analyses compare pregnancy rates [35] .
Several innovative analytic approaches have been used in recent studies. For example, two studies used data from serodiscordant couples which may help control for differences in exposure to an HIV-infected partner, and both highlight the importance of using various analytic techniques (such as restriction to non-condom users, or assessing male partner report of condom use) to assess whether primary findings remain robust (thereby testing concerns about the validity of data on self-reported sexual behaviors) [61, 63] . However, several methodological challenges remain, and are reviewed elsewhere, along with recommended approaches to improve the quality of evidence in future studies [35] .
We are aware of anecdotal evidence that a non-significant preliminary finding for the effect of DMPA use on HIV acquisition was not pursued for publication in at least one case, due to the lack of a statistically significant finding. This is problematic; if studies with significant results are more likely to be published, a systematic literature review is unable to capture the universe of relevant information on this issue [74] . However, funnel plots (Fig. 8) displayed only moderate asymmetry.
In addition to the limitations of individual studies, there are limitations to this systematic review. There is no agreed upon, comprehensive, objective method to assessing the quality of studies in this complex body of literature; conclusions may vary depending upon what quality criteria are applied. As noted above, discussions on ideal approaches to evaluating this literature should continue to evolve.
Unpublished evidence
For methodological reasons, we did not include unpublished analyses in this systematic review. Researchers have noted that differences between data presented in conference abstracts and published papers are "frequent and occasionally major," [75] and that "the inclusion of data from unpublished studies [in systematic reviews] can itself introduce bias" given that "unpublished trials may be of lower methodological quality than published trials." [76] Furthermore, there is no systematic manner in which to search grey literature, and moreover, thorough assessment of study quality is often challenging or impossible based on information provided in a conference presentation. We are aware of one analysis published subsequent to our cutoff date (January 15, 2014) [77] , and of four relevant presentations on this issue [78] [79] [80] [81] . Any analyses newly reported in academic journals since the cutoff for inclusion in this review will be carefully examined and reported at the next technical consultation on this issue.
Conclusions
We considered nine of 22 studies to be "informative but with important limitations".
Oral contraceptives
The preponderance of data suggests that OCs do not increase risk of HIV acquisition. Only one study (of eight considered "informative but with important limitations" which assessed OCs) reported a modestly elevated statistically significant risk estimate (adjHR 1.46, 95% CI 1.00-2.13); all other studies found no significant effect, including a study which provided separate information about COCs and POPs [62] . 4.5.2. Injectables 4.5.2.1. All injectables (i.e., either DMPA alone, or DMPA and NET-EN combined). The observational data on injectable contraceptive use and risk of HIV acquisition remain difficult to interpret. Modifications to our quality framework for selecting studies changed slightly the group of studies considered to be higher quality (i.e., classified as "meeting minimum quality criteria" in the previous review, or "informative but with important limitations" in the current review). Specifically, we removed one study with nonsignificant effects for DMPA from the higher quality group [51] and added one study with significant effects for both DMPA and NET-EN [42] . In addition, new sub-analyses by Heffron et al. [61] lend some additional confidence that incomplete statistical control for sexual behaviors (e.g., selfreported condom use, coital frequency) may not explain the statistically significant findings observed for injectables in their original analysis. Another separate new subanalysis by Heffron et al. suggested that the estimate for all injectables (as presented in the original paper) is similar in magnitude to the best possible approximation of an estimate for DMPA (as presented in the subanalysis). However, those sub-analyses contained few incident HIV infections, and some researchers have questioned whether condom use was over-reported based on the high pregnancy rates observed in this study [26, 29] .
On the other hand, one large, newly included study did not find statistically significant effects on HIV risk for either DMPA or NET-EN. Combining DMPA, NET-EN, and unspecified injectables into a single exposure category resulted in a significant finding (adjHR: 1.37, 95% CI 1.01-1.85) under a Cox proportional hazards model, and a similar but non-significant point estimate under a MSM approach (adjHR: 1.34, 95% CI 0.75-2.37) [62] . In addition, the modification to the quality framework relating to intersurvey interval resulted in the use of HC method estimates for the study by Myer et al. only from the first 6 month survey interval, as subsequent intervals were longer than 6 months [53] . The new DMPA point estimate remained nonsignificant, and was slightly smaller than the previous one (adjHR 0.96, 95% CI 0.58-1.59 in the previous review vs. adjHR 0.75, 95% CI 0.33-1.68 in the current), while the NET-EN estimate remained non-significant but with the direction of effect changed (from adjHR 0.79, 95% CI 0.31-2.20 previously vs. adjHR 1.60, 95% CI 0.63-4.09 currently). Finally, results from one study [57, 64] demonstrate a statistically significant effect of DMPA on HIV risk using a MSM approach but not a Cox model approach. Cox models are a closer approximation to the direct effect, our effect of interest. Thus, new data published between December 15, 2011 and January 15, 2014 for injectables, particularly DMPA, do not resolve the critical question of whether progestin-only injectables increase HIV risk.
NET-EN.
One previously identified study which was newly classified as "informative but with important limitations" reported a statistically significant increased risk of HIV acquisition with NET-EN [42] . One new study reported no increased HIV risk with NET-EN use [62] , and the direction of another estimate (for the study in which we restricted to only data from the 6-month follow-up visit) reversed but remained non-significant (estimate changed from adjIRR 0.79, 95% CI 0.31-2.20 previously, to adjIRR 1.60, 95% CI 0.63-4.09 currently) [53] . These new data add heterogeneity to evidence on NET-EN.
Implants
Data on contraceptive implants and HIV acquisition are extremely limited. No studies have suggested a statistically significant increased risk of HIV acquisition among implant users, though the limited number of studies examining this method and the wide confidence intervals for existing estimates preclude clear interpretation of the effects of implants on HIV acquisition. Ideally, future studies assessing implants will separately assess etonogestrel and levonorgestrel implants, which may have different biological effects.
Summary
In conclusion, and consistent with our previous review, evidence available at present suggests that OCs do not increase risk of HIV acquisition. One new study suggests that this finding may extend to both COCs and POPs, and adds to very limited data assessing non-injectable progestinonly HC methods. Uncertainty persists regarding the association between DMPA and HIV risk. Newly published analyses are in the direction of an elevated risk; taken together with prior evidence, the new data lead to a moderate increase in the consistency of estimates of the effect of DMPA on HIV risk. Still, several of the largest studies reported no statistically significant increased HIV risk among DMPA users, contributing to continued uncertainty. None of three studies in our previous review suggested a significantly increased risk for NET-EN, whereas one of five available estimates in our current review does. Four of the five studies that presented both DMPA and NET-EN estimates reported measures of effect for NET-EN that were slightly or substantially higher than for DMPA, though the 95% confidence intervals overlapped substantially in all cases. Data are limited for implants; neither of two estimates showed a statistically significant increased risk, but only one was considered "informative but with important limitations" and this estimate had limited statistical power.
Women choosing progestin-only injectable contraceptives should be informed of the current uncertainty regarding whether use of these methods is associated with an increased risk of HIV acquisition, and similar to all women at risk of HIV, should be empowered to access and use condoms and other HIV preventative measures. Access to a range of contraceptive options and to HIV preventive measures is critical. Data for OCs do not suggest an increased risk of HIV acquisition, but programs, practitioners, and women urgently need guidance on how to optimize health decisions in the face of inconclusive data for progestin-only injectable contraception and of limited data for other HC methods.
